

REMARKS

Claims 8-11 are now pending in the present application. After a discussion with the Examiner on January 24, 2008, Claim 8 has been amended. No new matter has been added. Support for this amendment is found generally throughout the specification and specifically at page 3, paragraph 35.

Claim 8 has been amended to make clear the advantage of injecting synthetic blood around the tumor or target cells. Solid tumors are often resistant to radiation and chemotherapy. Because synthetic blood has a much smaller molecular size than red blood cells, as well as higher solubility coefficient for oxygen and lower viscosity than blood, it can deliver air to tiny capillaries. Synthetic blood can carry oxygen through constricted or partially blocked blood vessels to areas of the target tissues that red blood cells cannot reach due to their larger size. Furthermore, synthetic blood more readily releases oxygen to tissues than red blood cells. They can provide conditions for improved perfusion in solid tumors, thereby resulting in higher tumor oxygen tension. Therefore, administration of synthetic blood prior to ultrasound energy exertion will increase the efficacy of treatment.

Accordingly, Applicant respectfully submits that claim 8 is clearly allowable. Furthermore claim 9-11 are allowable since they depend from an allowable base claim.

Applicants respectfully reserve the right to pursue the claims as originally filed in one or more continuations and/or divisional patent applications.

CONCLUSION

Applicants' attorney believes this application is in condition for allowance.
Should any unresolved issues remain, Examiner is invited to call Applicants' attorney at the telephone number indicated below.

Respectfully submitted,

January 30, 2008

/Joseph A. Sawyer, Jr./

Joseph A. Sawyer, Jr.

Reg. No. 30,801

Customer Number 29141

(650) 493-4540	Voice
(650) 493-4549	Facsimile